Skip to main content

Table 3 Adverse event summary for the control group in Attacks 3 and 4 (safety population)

From: Safety findings from CENTURION, a phase 3 consistency study of lasmiditan for the acute treatment of migraine

 

Control Group (N=266)a

Placebo

Lasmiditan 50mgb

Attacks treated

3rd or 4th

3rd or 4th

% reporting common TEAEc

  

- Dizziness

2.6

5.6

- Paresthesia

1.5

1.1

- Fatigue

0.8

2.3

  1. Abbreviations : AE adverse event, TEAE treatment-emergent AE
  2. aFor patients who treated 4 attacks
  3. bNo deaths, serious AEs, or AEs leading to discontinuation with lasmiditan 50 mg
  4. cCommon TEAE – reported in >2 % of LTN group
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us